A new therapy for breast cancer using proteins from specific fibroblasts
A novel breast cancer therapy based on secreted protein ligands from CD36+ fibroblasts
This study is exploring a new way to treat breast cancer by using special proteins from certain cells in the body to help improve existing treatments, aiming to make them more effective for patients with different types of breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nevada Reno NIH-funded |
| Lab location | 1 site (Reno, United States) |
| Project ID | NIH-11056894 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating breast cancer by utilizing secreted protein ligands from CD36+ fibroblasts. The study aims to reprogram cancer-associated fibroblasts (CAFs) to enhance therapeutic strategies while targeting both the tumor and the surrounding fibroblasts. By identifying and testing specific proteins that can suppress tumor growth and promote the expression of CD36 in CAFs, the research seeks to improve treatment outcomes for various breast cancer subtypes. Patients may benefit from this innovative therapy that addresses the limitations of current CAF-targeted treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer, particularly those with subtypes that are currently difficult to treat.
Not a fit: Patients with non-breast cancer conditions or those whose tumors do not involve CAFs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective therapy for breast cancer that minimizes off-target effects.
How similar studies have performed: While targeting CAFs is a growing area of interest, this specific approach using CD36+ fibroblasts and their secreted proteins is novel and has not been extensively tested in prior research.
Where this research is happening
Reno, United States
- University of Nevada Reno — Reno, United States (Active)
Researchers
- Principal investigator: Parvin, Bahram a. — University of Nevada Reno
- Study coordinator: Parvin, Bahram a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.